LOCALLY ADVANCED BREAST CANCER

This early-phase study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple-negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants with advance…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with specific HER2-positive, HER2-low…

This study tests a new drug called HRS-8080 in 240 women with advanced breast cancer that has worsened after hormone therapy. Participants will either receive HRS-8080 or another treatment chosen by their doctor. The main goal is to see if HRS-8080 can delay cancer growth longer …

This phase 3 study tests whether a new drug called palazestrant, combined with ribociclib, works better than the standard treatment (letrozole plus ribociclib) for people with a common type of advanced breast cancer (ER+/HER2-). About 1,000 adults who have not had prior treatment…

This study tests a new drug called FWD1802 in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find a safe dose and see if it shrinks tumors. About 99 women with cancer that has spread or cannot be removed by surgery will take part.

This early-phase study is testing a new drug called OP-1250 (palazestrant) combined with other targeted therapies for people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find the safest dose and understand side effects. About 190 adu…

This study tests whether adding the drug pyrotinib to standard trastuzumab therapy can further reduce the chance of breast cancer returning in women with HER2-positive breast cancer who still have cancer cells after initial chemotherapy and anti-HER2 treatment. About 316 women wi…

This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The cancer must have a specific gene change (PIK3CA mutation) and be hormone receptor-positive and HER2-negative. About …

This study tests whether a 24-week exercise program (aerobic and strength training, 3 times a week) can help prevent breast cancer from returning in people with early-stage breast cancer. About 2,156 participants who have completed surgery and any chemotherapy or radiation will t…

This study tests if a special mammogram with contrast dye can predict whether breast cancer has been completely eliminated by chemotherapy, just as well as an MRI does. About 30 women with locally advanced breast cancer will get 1-2 of these mammograms during or after chemo, befo…

This study tests whether combining the drug memantine with a structured exercise program can improve memory and thinking problems (often called 'chemo brain') in women undergoing chemotherapy for early-stage breast cancer. About 90 participants will be split into three groups: on…

This study aims to match breast cancer patients with the most effective experimental drugs based on their tumor's unique features. Up to 5,000 participants will receive standard chemotherapy plus an experimental agent before surgery. Researchers will use MRI scans, tissue, and bl…